Market Eyes LiveAbbvie Inc. (ABBV) Stock Rating & Analysis
MELANY's data-driven read on Abbvie Inc. · Pharmaceutical Preparations.
AbbVie is a pharmaceutical firm with strong exposure to immunology (Humira, Skyrizi, and Rinvoq) and oncology (Imbruvica and Venclexta), spun off from Abbott in early 2013. Its 2020 acquisition of Allergan added products and drugs in aesthetics including Botox, and its 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) further supplement its portfolio.
Why ABBV scores 70/100
MELANY scores Abbvie Inc. 70/100 by weighing eight factors. Here is how ABBV breaks down.
Whether the price looks cheap or expensive against earnings, growth, and peers.
- Forward P/E 15.8x, earnings growth accelerating
- PEG ratio 0.44 (< 1 = undervalued)
Margins, returns on capital, and balance-sheet strength.
- Gross margin 72%
Direction and relative strength of the recent share-price trend.
- Price +5.9% above 50-day MA
- 50-day MA above 200-day (golden cross zone)
History of beating or missing estimates, and where estimates are heading.
- Beat EPS estimates 3 of last 4 quarters
What Wall Street price targets and revisions are signalling.
Near-term events that could move the stock.
Upside weighed against volatility and drawdown risk.
How the current rate and market regime suits this kind of company.
Key risks for ABBV
- Trading near 52-week high, limited upside without new positive catalyst
Sector and theme context
Abbvie Inc. sits in the Healthcare sector theme, which MELANY currently rates 42/100 for strength. Theme strength feeds ABBV's momentum and catalyst factors above.
ABBV trade plan (members only)
MELANY has a full position plan for Abbvie Inc.: a smart entry zone, an alert level, position sizing, and quarterly review triggers. It unlocks free when you create an account.
How MELANY rates ABBV
MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. Abbvie Inc.'s 70/100 reflects mature factor weighting for its profile. Position framework managed by score-based check-ins, not a fixed holding period.
Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.
Frequently asked questions about ABBV
Is Abbvie Inc. (ABBV) a buy?
As of 2026-08-21, MELANY rated Abbvie Inc. Highest Conviction with a composite score of 70/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.
What is Abbvie Inc.'s MELANY score?
Abbvie Inc. (ABBV) has a MELANY composite score of 70/100, combining valuation, business quality, price momentum, earnings track record, analyst sentiment, catalyst setup, risk-adjusted profile, and macro fit.
How is the ABBV stock rating calculated?
MELANY scores ABBV from 0 to 100 across eight weighted factors using live market and fundamental data, then refreshes the rating automatically as new data arrives.
Should I buy Abbvie Inc. stock?
That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates Abbvie Inc. (ABBV) Highest Conviction with a composite of 70/100 as of 2026-08-21. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.
What is the ABBV stock price forecast?
MELANY does not publish price targets or forecasts for ABBV. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 70/100 across eight factors for Abbvie Inc., and re-scores automatically as new price, earnings, and fundamental data arrive.
Is ABBV stock overvalued or undervalued?
MELANY's valuation factor currently reads 54/100 for Abbvie Inc., where a higher score means the price looks more attractive against earnings, growth, and peers. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives ABBV's read.
What price should I buy ABBV at?
Rather than chasing the current price, MELANY computes a smart entry zone for ABBV: the price area where risk and reward actually favor a new position, plus an alert level and position sizing. The exact levels unlock free when you create a Market Eyes Live account.
What are the risks of buying ABBV stock?
The top risks MELANY currently flags for Abbvie Inc.: Trading near 52-week high, limited upside without new positive catalyst. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.
Is Abbvie Inc. a good long-term investment?
For long-term durability the two factors that matter most are business quality, which MELANY scores 100/100 for Abbvie Inc., and earnings track record, at 65/100. The 70/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.
Will ABBV stock go up?
Nobody can promise a stock's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's price momentum factor reads 73/100 for ABBV right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.
How current is this ABBV rating?
The rating on this page is a snapshot of MELANY's read as of 2026-08-21. The price shown updates live, but the score is not recomputed on this page. MELANY re-scores ABBV continuously as new price, earnings, and fundamental data arrive, and that current rating is free in the app.
ABBV's entry zone, live alerts, and full trade plan are free either way. The app is our flagship.